Long COVID - review of many subtypes
Identifying subtypes of Long COVID: a systematic review
Lancet eClinicalMedicine, Volume 91, 103705 January 2026
Bingyi Wanga,b,c,d,e,f,n wangbingyi@chevidence.cn ∙ Xufei Luoa,b,c,d,e,n luoxf2016@gmail.com ∙ Meihua Wug wumeihua@chevidence.cn ∙ Zijun Wanga,b,c,d,e wangzijun@chevidence.cn ∙ Jie Zhanga,b,c,d,e zhangjie@chevidence.cn ∙ Zijing Wangg wangzijing@chevidence.cn ∙ et al. Show
Background Long COVID, a persistent condition following SARS-CoV-2 infection, exhibits diverse symptoms across multiple organ systems. This study aims to summarize the existing clustering and classification approaches to support the management of Long COVID.
Methods Following PRISMA guidelines, we systematically searched PubMed, Embase, Web of Science, and Google Scholar from their inception to January 21, 2025, and updated the search on October 1, 2025, to identify studies that presented a way to categorize Long COVID patients or symptoms. Data extraction and quality assessment were conducted for eligible studies. We presented symptom co-occurrence networks, and performed meta-analysis to estimate the percentage of different organ system-based symptom clusters. In addition, we conducted an exploratory analysis of the determinants of different symptom clusters. The protocol was registered in OSF (https://doi.org/10.17605/OSF.IO/J483F).
Findings
Forty-seven cohort studies and 17 cross-sectional studies categorizing Long COVID subtypes or symptoms were included, encompassing 2.43 million participants across 20 countries. The methodological quality of the cohort studies was on average high (mean Newcastle–Ottawa scale score: 7.5/9), and of the 17 cross-sectional studies moderate (mean Joanna Briggs Institute tool score: 0.61/1.00). Patients or symptoms were categorized either according to the co-occurrence of symptoms (n = 30 studies, 46.9%); by the affected organ system (n = 16, 25.0%); by severity stratification (n = 9, 14.1%); by clinical indicators (n = 3, 4.7%); or by using other ways of classification (n = 6, 9.4%). Among the 30 studies defining patient clusters by the co-occurrence of symptoms, fatigue was the most frequently used descriptor for a cluster, either alone or together with other symptoms (n = 15 studies). Pairwise co-occurrence analysis revealed some commonly used symptom dyads, including olfactory–gustatory dysfunction (n = 10 times), anxiety–depression (n = 10) and joint pain/swelling–muscle pain (n = 9). Fatigue was a recurrent core symptom, frequently co-occurring with joint pain/swelling (n = 9 times) or muscle pain (n = 7), cognitive symptoms (n = 7), and dyspnea (n = 7). Meta-analysis of the organ system-based subtypes showed that respiratory symptom cluster had the highest pooled percentage (47% [95% CI: 29%–65%]), followed by neurological (31% [95% CI: 3%–60%]) and gastrointestinal clusters (28% [95% CI: 0%–57%]). These percentages represent the proportion of Long COVID patients with each symptom cluster within the 16 included organ system-based subtyping studies, not population-level prevalence of Long COVID. Exploratory analysis indicated that symptom subtypes were influenced by factors such as sex, age, virus variant, and comorbidities.
Interpretation This review identified four major approaches for categorizing Long COVID patients and their symptoms. Symptom co-occurrence and organ system were the most commonly used subtypes used in categorization. Fatigue and olfactory–gustatory dysfunction emerged as recurrent core symptoms across multiple subtypes of Long COVID.
Review of this study at TrialSiteNews
Related in VitaminDWiki
- Long COVID and Long COVID Vaccines are disturbingly similar
- COVID and Long-COVID Association with Lower Vitamin D Levels - Perplexity AI
- Long-COVID may wear out the immune system (Vitamin D might restore it)
- How vitamin D benefits normal organs and Long-COVID organs
- Long-COVID: Vitamin D was the only statistically significant factor
- LONG-COVID may be permanent in 1 in 200 of people infected